More about

Dapagliflozin

News
June 17, 2022
7 min read
Save

A new horizon for guideline-directed medical therapy in HFpEF

A new horizon for guideline-directed medical therapy in HFpEF

Approximately 52% of patients with HF are categorized as those with a preserved ejection fraction. Hospitalizations in this patient population are continuing to increase.

News
June 03, 2022
2 min read
Save

ADA Standards of Care update reflects new data on CV, kidney disease in type 2 diabetes

ADA Standards of Care update reflects new data on CV, kidney disease in type 2 diabetes

The American Diabetes Association announced updates to its 2022 Standards of Medical Care in Diabetes to reflect new data on cardiovascular outcomes with diabetes and kidney disease and use of SGLT2 inhibitors.

News
June 01, 2022
2 min read
Save

Top news of May: Implications of high HDL, celebrating 20 years of TAVR and more

Top news of May: Implications of high HDL, celebrating 20 years of TAVR and more

Healio and Cardiology Today have compiled a list of the most-read news in cardiology of May 2022.

News
May 09, 2022
1 min read
Save

Top in cardiology: Apple Watch app; topline data on dapagliflozin

Top in cardiology: Apple Watch app; topline data on dapagliflozin

At Heart Rhythm 2022, researchers reported that applying an artificial intelligence to an Apple Watch ECG can detect left ventricular dysfunction in a nonclinical setting.

News
May 05, 2022
1 min read
Save

DELIVER topline results: Dapagliflozin reduces CV death, worsening HF in EF more than 40%

DELIVER topline results: Dapagliflozin reduces CV death, worsening HF in EF more than 40%

Topline findings from the phase 3 DELIVER trial show dapagliflozin significantly reduced risk for CV death or worsening HF compared with placebo in adults HF with mildly reduced or preserved ejection fraction, AstraZeneca announced.

News
April 28, 2022
2 min read
Save

Dapagliflozin was well tolerated among patients hospitalized with COVID-19

Dapagliflozin was well tolerated among patients hospitalized with COVID-19

Among patients hospitalized with COVID-19, dapagliflozin was well tolerated and did not increase risk of AKI in patients, according to data published in the Clinical Journal of the American Society of Nephrology.

News
April 26, 2022
2 min read
Save

Dapagliflozin safe, well tolerated among adults with frailty: DAPA-HF

Dapagliflozin safe, well tolerated among adults with frailty: DAPA-HF

The SGLT2 inhibitor dapagliflozin safely reduced risk for worsening HF or CV death among adults with HF with reduced ejection fraction compared with placebo regardless of frailty status, researchers reported.

News
January 13, 2022
2 min read
Save

GLP-1, SGLT2 combination therapy provides largest weight loss for women with PCOS

GLP-1, SGLT2 combination therapy provides largest weight loss for women with PCOS

Combination therapy with a GLP-1 receptor agonist and an SGLT2 inhibitor may provide better weight-loss benefits than a single agent for women with polycystic ovary syndrome and obesity, according to study data.

News
December 16, 2021
1 min read
Save

Dapagliflozin seen as safe for reducing adverse kidney outcomes in patients with CKD

An analysis of data showed patients with chronic kidney disease and type 2 diabetes who were or were not prescribed mineralocorticoid receptor antagonists saw reductions in major adverse kidney outcomes after taking dapagliflozin.

News
November 23, 2021
1 min read
Save

Dapagliflozin significantly slows rate of kidney decline in patients with CKD

For patients with chronic kidney disease, dapagliflozin slowed long-term decreases in the eGFR.

View more